U.S. Acellular Dermal Matrices MarketSize and Trends

The U.S. acellular dermal matrices market is estimated to be valued at US$ 2.79 Bn in 2023 and is expected to exhibit a CAGR of 11% during the forecast period (2023-2030).

Figure 1. U.S. Acellular Dermal Matrices Market Share (%), By Application, 2023

Figure 2. U.S. Acellular Dermal Matrices Market Share (%), By Origin, 2023

U.S. acellular dermal matrices market is segmented into origin, application, place of setting, and region.

By origin, the market is segmented into human dermis, porcine dermis, and bovine dermis. Out of which, the human dermis segment is expected to hold a dominant position in the U.S. acellular dermal matrices market during the forecast period. Human dermis is preferred by surgeons and patients as it minimizes the risk of rejection or allergic reaction. As the material is sourced from human tissue, it is less likely to trigger an immune response in the recipient's body compared to porcine or bovine tissues. This reduces complications and allows for faster healing times.
By application, the market is segmented into [acute wounds (burns, trauma, cancers, and infections), chronic wounds (diabetic foot ulcers, venous leg ulcers, pressure ulcer, and others), and reconstruction procedures (abdominal wall procedures, breast procedures, orthopedic procedures, and others]. Out of which, the reconstruction procedures segment is expected to dominate the market over the forecast period, due to the increasing number of reconstruction procedures performed in the U.S. For instance, in October 2022, according to data published by Yale Medicine, in 2020, nearly 138,000 breast reconstructions were done in the U.S. among women who needed a mastectomy to either eliminate an active breast cancer or prevent it from occurring.
By place of setting, the market is segmented into hospitals, ambulatory surgical centers, and office based. Out of which, the hospitals segment is expected to dominate the market over the forecast period, due to increasing adoption of organic growth strategies such as launch of new hospitals in the U.S. For instance, in January 2020, Hospital for Special Surgery, a medical center focused on musculoskeletal health, launched a new hospital in Florida, U.S.

U.S. Acellular Dermal Matrices Market: Trends

Increasing adoption of inorganic growth strategies such as agreement: Increasing adoption of inorganic growth strategies, such as agreements, by the key market players is expected to drive the growth of the U.S acellular dermal matrices market over the forecast period. For instance, on March 22, 2023, Aziyo Biologics, Inc, a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, and Sientra, Inc., a medical aesthetics company focusing on plastic surgery, announced that they have entered into an agreement to expand the distribution of Aziyo’s SimpliDerm product line. Under the agreement terms, Aziyo Biologics, Inc will grant Sientra, Inc., certain non-exclusive rights in the U.S. to market, sell, and distribute Aziyo’s SimpliDerm for selective use in reconstruction surgery. SimpliDerm is a pre-hydrated human acellular dermal matrix (hADM) that uses a proprietary process to preserve key growth factors of native dermis that supports faster integration and more rapid revascularization while demonstrating a lower risk of inflammatory response.

U.S. Acellular Dermal Matrices Market - Drivers

Increasing number of surgeries: Increasing number of surgeries performed is expected to drive the growth of the U.S. acellular dermal matrices market over the forecast period. For instance, on September 21, 2023, according to data published by Cleveland Clinic, more than 1 million hernia surgeries are performed in the U.S. annually.
Increasing adoption of organic growth strategies such as product launch: Increasing adoption of organic growth strategies such as product launch by the key market players is expected to drive the growth of the U.S. acellular dermal matrices market over the forecast period. For instance, in November 2021, Sanara MedTech Inc., a provider of products and technologies for surgical and chronic wound care dedicated in improving patient outcomes, launched two new innovative extracellular matrix products named- FORTIFY TRGT and FORTIFY FLOWABLE. FORTIFY FLOWABLE Extracellular Matrix is an advanced wound care device that presents the SIS ECM technology in a way that can fill irregular wound shapes and depths.